Late recurrence (LR) of bladder cancer after radical cystectomy (RC) is rare, and few studies have been conducted. We report a case of local LR of bladder cancer 10.3 years after RC. The pathology at RC was almost carcinoma in situ (CIS) only. The patient underwent metastasectomy, and treatment with an immune checkpoint inhibitor (ICI) achieved a complete response (CR). A 61-year-old woman was referred to our hospital for macrohematuria and bladder irritability in June 2012. She underwent RC along with pelvic lymph node dissection and ileal conduit creation. The pathologic findings were CIS, G2>G3, pT1, pN0. She visited our hospital with complaints of lower abdominal discomfort in November 2022, and recurrence was found on the pelvic floor by abdominal computed tomography. Metastasectomy confirmed metastasis of urothelial carcinoma. As salvage therapy, systemic chemotherapy with a platinum agent and an ICI were administered, leading to CR. Long-term follow-up should be considered for patients with bladder cancer, even for early-stage CIS-only tumors. Metastasectomy could be the primary option for LR of bladder cancer after RC.
| Published in | International Journal of Clinical Urology (Volume 8, Issue 2) |
| DOI | 10.11648/j.ijcu.20240802.14 |
| Page(s) | 35-38 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Late Local Recurrence, Bladder Cancer, Carcinoma in Situ, Metastatectomy
| [1] | Tachibana M, Tsubouchi K, Fukuhara Y et al.: Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer. Anticancer Res. 2023 43(8): 3607-3613. |
| [2] | Samantha Conroy, Ibrahim Jubber, Aidan P Noon et al.: Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial. BJU international. 2024 Sep 26. |
| [3] | Vincenzo Serretta: BCG and bladder cancer. Forty-eight years after Morales report. Urologia. 2024 91(3): 459-467. |
| [4] | Stein JP, Lieskovsky G, Cote R et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001 19: 666-675. |
| [5] | Bochner B, Kattan MW and Vora KC: Post-operative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol; 2006 24: 3967-3972. |
| [6] | Yoo SH, Kim H, Kwak C et al.: Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes. Urol Int. 2019 103(3): 291-296. |
| [7] | Hirata Y, Higuchi M, Osawa T et al.: Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. J Urol. 2022 29(10): 1140-1146. |
| [8] | Linder BJ, Boorjian SA, Hudolin T et al.: Late recurrence after radical cystectomy: patterns, risk factors and outcomes. J Urol 2014 191: 1256-1261. |
| [9] | Dawson S, Cha EK, Falavolti C et al.: Late recurrences following radical cystectomy have distinct prognostic and management considerations. J Urol; 2020 204: 460-465. |
| [10] | Hassan JM, Cookson MS, Smith, Jr JA et al.: Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. J Urol; 2004 172: 882-884. |
| [11] | Zehnder P, Moltzahn F, Daneshmand S et al.: Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy. BJUI; 2014 113: 65-69. |
| [12] | Villegas E, Lajkosz K, Din S et al.: Long-term recurrence risk, metastatic potential and length of cystoscopic surveillance of low-grade non-muscle invasive bladder cancer. J Urol. 2024 29: 101097. |
| [13] | Naspro R, La Croce G, Finati M et al.: Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants. Urol Oncol. 2022 40(2): 61. e9-61. e19. |
| [14] | Beijert IJ, Hentschel AE, Bründl J et al.: Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum. Eur Urol Oncol. 2023 6(2): 214-221. |
| [15] | Niyati Lobo, Zhigang Duan, Akshay Sood et al.: Association of Age with Non-muscle-invasive Bladder Cancer: Unearthing a Biological Basis for Epidemiological Disparities? European urology oncology. 2024 7(5): 1069-1079. |
| [16] | Witjes JA, Bruins HM, Cathomas R et al.: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol. 2021 79(1): 82-104. |
APA Style
Nishimura, M., Ueno, S., Nomura, T. (2024). Late Local Recurrence of Carcinoma in situ - Only Bladder Cancer. International Journal of Clinical Urology, 8(2), 35-38. https://doi.org/10.11648/j.ijcu.20240802.14
ACS Style
Nishimura, M.; Ueno, S.; Nomura, T. Late Local Recurrence of Carcinoma in situ - Only Bladder Cancer. Int. J. Clin. Urol. 2024, 8(2), 35-38. doi: 10.11648/j.ijcu.20240802.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcu.20240802.14,
author = {Masanori Nishimura and Syun Ueno and Takeshi Nomura},
title = {Late Local Recurrence of Carcinoma in situ - Only Bladder Cancer
},
journal = {International Journal of Clinical Urology},
volume = {8},
number = {2},
pages = {35-38},
doi = {10.11648/j.ijcu.20240802.14},
url = {https://doi.org/10.11648/j.ijcu.20240802.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20240802.14},
abstract = {Late recurrence (LR) of bladder cancer after radical cystectomy (RC) is rare, and few studies have been conducted. We report a case of local LR of bladder cancer 10.3 years after RC. The pathology at RC was almost carcinoma in situ (CIS) only. The patient underwent metastasectomy, and treatment with an immune checkpoint inhibitor (ICI) achieved a complete response (CR). A 61-year-old woman was referred to our hospital for macrohematuria and bladder irritability in June 2012. She underwent RC along with pelvic lymph node dissection and ileal conduit creation. The pathologic findings were CIS, G2>G3, pT1, pN0. She visited our hospital with complaints of lower abdominal discomfort in November 2022, and recurrence was found on the pelvic floor by abdominal computed tomography. Metastasectomy confirmed metastasis of urothelial carcinoma. As salvage therapy, systemic chemotherapy with a platinum agent and an ICI were administered, leading to CR. Long-term follow-up should be considered for patients with bladder cancer, even for early-stage CIS-only tumors. Metastasectomy could be the primary option for LR of bladder cancer after RC.
},
year = {2024}
}
TY - JOUR T1 - Late Local Recurrence of Carcinoma in situ - Only Bladder Cancer AU - Masanori Nishimura AU - Syun Ueno AU - Takeshi Nomura Y1 - 2024/11/12 PY - 2024 N1 - https://doi.org/10.11648/j.ijcu.20240802.14 DO - 10.11648/j.ijcu.20240802.14 T2 - International Journal of Clinical Urology JF - International Journal of Clinical Urology JO - International Journal of Clinical Urology SP - 35 EP - 38 PB - Science Publishing Group SN - 2640-1355 UR - https://doi.org/10.11648/j.ijcu.20240802.14 AB - Late recurrence (LR) of bladder cancer after radical cystectomy (RC) is rare, and few studies have been conducted. We report a case of local LR of bladder cancer 10.3 years after RC. The pathology at RC was almost carcinoma in situ (CIS) only. The patient underwent metastasectomy, and treatment with an immune checkpoint inhibitor (ICI) achieved a complete response (CR). A 61-year-old woman was referred to our hospital for macrohematuria and bladder irritability in June 2012. She underwent RC along with pelvic lymph node dissection and ileal conduit creation. The pathologic findings were CIS, G2>G3, pT1, pN0. She visited our hospital with complaints of lower abdominal discomfort in November 2022, and recurrence was found on the pelvic floor by abdominal computed tomography. Metastasectomy confirmed metastasis of urothelial carcinoma. As salvage therapy, systemic chemotherapy with a platinum agent and an ICI were administered, leading to CR. Long-term follow-up should be considered for patients with bladder cancer, even for early-stage CIS-only tumors. Metastasectomy could be the primary option for LR of bladder cancer after RC. VL - 8 IS - 2 ER -
Department of Urology, Misugikai Sato Hospital, Osaka, Japan
